AC Immune Trial Shows Early Signs of Immunotherapy's Potential to Slow Parkinson's Disease Progression

AC Immune SA's Phase 2 VacSYn trial results show that its anti-alpha-synuclein active immunotherapy, ACI-7104.056, may slow the progression of Parkinson's disease. The trial showed stabilization of disease-related biomarkers, potential disease modification, and a robust antibody response against the immunizing a-syn target antigen. The results suggest that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of the disease. Final data from Part 1 of the VacSYn trial are expected in mid-2026.